Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping
January 23 2024 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the full
commercial release of the Stratys™ system, the Company’s system for
high throughput optical genome mapping (OGM).
As part of an early access program, the following 10 sites have
adopted a total of 11 Stratys systems:
- BC Cancer - Vancouver (Vancouver,
British Columbia)
- Hamilton Health Sciences (Hamilton,
Ontario)
- Henry Ford Health System (Michigan,
United States)
- National Guard Hospital (Riyadh, Saudi
Arabia)
- NHS Northwest Genomic Laboratory Hub
(Manchester, United Kingdom)
- Radboud University Medical Center
(Nijmegen, Netherlands)
- UZ Brussel and Cliniques universitaires
Saint-Luc (Brussels, Belgium)
- Vancouver General Hospital (Vancouver,
British Columbia)
- Additional sites that Bionano is not
able to name publicly include a United States-based high-volume
centralized reference laboratory and a United States-based leading
academic medical center specializing in cancer treatment
Alexander Hoischen, PhD, associate professor of genomic
technologies at Radboud University Medical Center,
commented, “The data quality for Stratys matches the high
standards of the established Saphyr® system, and the newly achieved
throughput is amazing. Stratys is the next evolution of OGM, with
significantly and impressively improved throughput. This
scalability aligns nicely with recently achieved automated lab
workflow for DNA isolation and improved automated analysis and
reporting through VIA™ software. Smart design also allows higher
flexibility and faster processing per sample when compared to the
Saphyr system. I am convinced Stratys will enable even more
innovative clinical research applications, particularly medium to
high throughput analysis, and may even have the potential to enable
diagnostic applications in the future. At Radboud University
Medical Center, we are excited to stay at the forefront of OGM use
for heme-oncology as well as rare disease discoveries.”
Bionano’s Stratys system for OGM offers increased flexibility
and throughput capabilities to address the needs of mid and
high-volume users. The throughput of the Stratys instrument is up
to four times greater than that of Bionano’s Saphyr® instrument, it
is compatible with the latest G2 chemistries, and has a potential
sample-to-answer time of 3 days for hematological samples
interrogated across the whole genome at high sensitivity to rare
variants. The system is designed for maximum lab flexibility by
enabling up to 12 single sample chips, each with the ability to
collect data for a different application, accessible as they
complete runs, and without the need to batch multiple samples on a
consumable.
The Stratys system is supported by the Stratys™ Compute
workstation, which offers accelerated data processing powered by
NVIDIA graphics processing units (GPUs). Stratys Compute provides
advanced computational technology at the bench with the potential
to enable faster and more accurate genome analysis without a
requirement to be installed in a data center.
“The Stratys system’s intuitive design was created with customer
feedback in mind, in order to offer flexibility that can
accommodate labs’ irregular workflows. Stratys uses the latest
imaging and data processing technologies, and it is compatible with
all current and planned automated elements in Bionano’s
comprehensive sample to report workflow. We look forward to seeing
how Stratys will transform the way labs approach genome analysis. I
want to congratulate everyone who was involved in this exciting
product launch,” stated Mark Oldakowski, chief operating officer of
Bionano.
Erik Holmlin, PhD, president and chief executive officer of
Bionano, commented, “We believe today marks an important day for
anyone seeking to implement OGM at scale, with the announcement of
commercial availability of Stratys, the first high throughput OGM
system, which can shorten time-to-results, reduce hands-on-time and
help reveal new actionable insights across research applications
including heme malignancies, constitutional genetic disorders and
cell and gene therapy. We launched an early access program for our
Stratys system in 2023 to great enthusiasm, with orders exceeding
our initial offering of 10 systems, many from new OGM adopters. We
are excited to see these early access sites partner with us as we
extend Stratys adoption across the world.”
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
The Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. The Company additionally offers
nucleic acid extraction and purification solutions using
proprietary isotachophoresis (ITP) technology. For more
information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Bionano’s OGM products are for research use only and not for use
in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “believe,” “can,” “plan,” “potential,” “will”
and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) convey
uncertainty of future events or outcomes and are intended to
identify these forward-looking statements. Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the potential of the Stratys system to increase
sample throughput compared to the Saphyr system; the ability and
utility of the Stratys system workflow to provide a sample to
answer time of 3 days; the ability and utility of the Stratys
system to maximize lab flexibility; the ability and utility of
Stratys Compute to enable faster and more accurate genome analysis;
the ability and utility of the Stratys system to shorten
time-to-results, reduce hands-on-time and help reveal new
actionable insights in research applications including heme
malignancies, constitutional genetic disorders and cell and gene
therapy; the potential of the Stratys system to accelerate the
adoption of OGM and overcome barriers to adoption of OGM by medium-
and high-volume users; our ability to drive adoption of the Stratys
system; the potential of the Stratys system to enable diagnostic
applications; and execution of our stated strategies and plans.
Each of these forward-looking statements involves risks and
uncertainties. Actual results or developments may differ materially
from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of geopolitical
and macroeconomic developments, such as recent and potential future
bank failures, supply chain disruptions, global pandemics,
inflation and the ongoing conflicts between Ukraine andRussian and
Israel and Hamas, on our business and the global economy; general
market conditions; the failure of the Stratys system to increase
sample throughput; the failure of the Stratys system to increase
sample throughput compared to the Saphyr system; the failure of the
Stratys system workflow to provide a sample to answer time of 3
days; the failure of the Stratys system to maximize lab
flexibility; the failure of Stratys Compute to enable faster and
more accurate genome analysis; the failure of the Stratys system to
shorten time-to-results, reduce hands-on-time and help reveal new
actionable insights in research applications including heme
malignancies, constitutional genetic disorders and cell and gene
therapy; the failure of the Stratys system to accelerate the
adoption of OGM and overcome barriers to adoption of OGM by medium-
and high-volume users; the failure of our ability to drive adoption
of the Stratys system; the failure of the Stratys system to enable
diagnostic applications; changes in the competitive landscape and
the introduction of competitive technologies or improvements to
existing technologies; changes in our strategic and commercial
plans; our need and ability to obtain sufficient financing to fund
our strategic plans and commercialization efforts, our ability to
effectively manage our uses of cash, and our ability to continue as
a “going concern”; the ability of medical and research institutions
to obtain funding to support adoption or continued use of our
technologies; and the risks and uncertainties associated with our
business and financial condition in general, including the risks
and uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2022 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTSCompany Contact:Erik
Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2024 to May 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From May 2023 to May 2024